Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DAISY: Phase 3 Study of Rilematovir in Infants and Children Hospitalized With RSV Infection
jRCT2031210193Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Sep 2021
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of rilematovir in respiratory syncytial virus disease (RSV) and acute respiratory illness (ARI) (4 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Respiratory Syncytial Virus (RSV) Recovery Scale (RRS). Started Sep 2021; status: completed.
02
Drugs
rilematovir
03
Conditions
respiratory syncytial virus disease (RSV)acute respiratory illness (ARI)
Beyond the preview
Go deeper on jRCT2031210193.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210193.